185 related articles for article (PubMed ID: 24243035)
21. Biochemical relapse following radical prostatectomy and miR-200a levels in prostate cancer.
Barron N; Keenan J; Gammell P; Martinez VG; Freeman A; Masters JR; Clynes M
Prostate; 2012 Aug; 72(11):1193-9. PubMed ID: 22161972
[TBL] [Abstract][Full Text] [Related]
22. Tpl2 induces castration resistant prostate cancer progression and metastasis.
Lee HW; Cho HJ; Lee SJ; Song HJ; Cho HJ; Park MC; Seol HJ; Lee JI; Kim S; Lee HM; Choi HY; Nam DH; Joo KM
Int J Cancer; 2015 May; 136(9):2065-77. PubMed ID: 25274482
[TBL] [Abstract][Full Text] [Related]
23. GPX2 overexpression is involved in cell proliferation and prognosis of castration-resistant prostate cancer.
Naiki T; Naiki-Ito A; Asamoto M; Kawai N; Tozawa K; Etani T; Sato S; Suzuki S; Shirai T; Kohri K; Takahashi S
Carcinogenesis; 2014 Sep; 35(9):1962-7. PubMed ID: 24562575
[TBL] [Abstract][Full Text] [Related]
24. Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression.
Shiota M; Takeuchi A; Song Y; Yokomizo A; Kashiwagi E; Uchiumi T; Kuroiwa K; Tatsugami K; Fujimoto N; Oda Y; Naito S
Endocr Relat Cancer; 2011 Aug; 18(4):505-17. PubMed ID: 21652770
[TBL] [Abstract][Full Text] [Related]
25. Pirin: a potential novel therapeutic target for castration-resistant prostate cancer regulated by miR-455-5p.
Arai T; Kojima S; Yamada Y; Sugawara S; Kato M; Yamazaki K; Naya Y; Ichikawa T; Seki N
Mol Oncol; 2019 Feb; 13(2):322-337. PubMed ID: 30444038
[TBL] [Abstract][Full Text] [Related]
26. Microdissecting the role of microRNAs in the pathogenesis of prostate cancer.
Ayub SG; Kaul D; Ayub T
Cancer Genet; 2015 Jun; 208(6):289-302. PubMed ID: 26004033
[TBL] [Abstract][Full Text] [Related]
27. [Non-coding RNAs in castration-resistant prostate cancer].
Xie GP; Jiang R
Zhonghua Nan Ke Xue; 2015 Nov; 21(11):1014-9. PubMed ID: 26738330
[TBL] [Abstract][Full Text] [Related]
28. MicroRNA-616 induces androgen-independent growth of prostate cancer cells by suppressing expression of tissue factor pathway inhibitor TFPI-2.
Ma S; Chan YP; Kwan PS; Lee TK; Yan M; Tang KH; Ling MT; Vielkind JR; Guan XY; Chan KW
Cancer Res; 2011 Jan; 71(2):583-92. PubMed ID: 21224345
[TBL] [Abstract][Full Text] [Related]
29. Regulation of the transcriptional coactivator FHL2 licenses activation of the androgen receptor in castrate-resistant prostate cancer.
McGrath MJ; Binge LC; Sriratana A; Wang H; Robinson PA; Pook D; Fedele CG; Brown S; Dyson JM; Cottle DL; Cowling BS; Niranjan B; Risbridger GP; Mitchell CA
Cancer Res; 2013 Aug; 73(16):5066-79. PubMed ID: 23801747
[TBL] [Abstract][Full Text] [Related]
30. SMYD3 as an oncogenic driver in prostate cancer by stimulation of androgen receptor transcription.
Liu C; Wang C; Wang K; Liu L; Shen Q; Yan K; Sun X; Chen J; Liu J; Ren H; Liu H; Xu Z; Hu S; Xu D; Fan Y
J Natl Cancer Inst; 2013 Nov; 105(22):1719-28. PubMed ID: 24174655
[TBL] [Abstract][Full Text] [Related]
31. microRNA-330 inhibits cell motility by downregulating Sp1 in prostate cancer cells.
Mao Y; Chen H; Lin Y; Xu X; Hu Z; Zhu Y; Wu J; Xu X; Zheng X; Xie L
Oncol Rep; 2013 Jul; 30(1):327-33. PubMed ID: 23670210
[TBL] [Abstract][Full Text] [Related]
32. MicroRNA-23b and microRNA-27b plus flutamide treatment enhances apoptosis rate and decreases CCNG1 expression in a castration-resistant prostate cancer cell line.
Pimenta RC; Viana NI; Amaral GQ; Park R; Morais DR; Pontes J; Guimaraes VR; Camargo JA; Leite KR; Nahas WC; Srougi M; Reis ST
Tumour Biol; 2018 Nov; 40(11):1010428318803011. PubMed ID: 30400755
[TBL] [Abstract][Full Text] [Related]
33. Impact of novel miR-145-3p regulatory networks on survival in patients with castration-resistant prostate cancer.
Goto Y; Kurozumi A; Arai T; Nohata N; Kojima S; Okato A; Kato M; Yamazaki K; Ishida Y; Naya Y; Ichikawa T; Seki N
Br J Cancer; 2017 Jul; 117(3):409-420. PubMed ID: 28641312
[TBL] [Abstract][Full Text] [Related]
34. miR-152 controls migration and invasive potential by targeting TGFα in prostate cancer cell lines.
Zhu C; Li J; Ding Q; Cheng G; Zhou H; Tao L; Cai H; Li P; Cao Q; Ju X; Meng X; Qin C; Hua L; Shao P; Yin C
Prostate; 2013 Jul; 73(10):1082-9. PubMed ID: 23460133
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection.
Patnaik SK; Kannisto E; Knudsen S; Yendamuri S
Cancer Res; 2010 Jan; 70(1):36-45. PubMed ID: 20028859
[TBL] [Abstract][Full Text] [Related]
36. Screening key microRNAs for castration-resistant prostate cancer based on miRNA/mRNA functional synergistic network.
Zhu J; Wang S; Zhang W; Qiu J; Shan Y; Yang D; Shen B
Oncotarget; 2015 Dec; 6(41):43819-30. PubMed ID: 26540468
[TBL] [Abstract][Full Text] [Related]
37. Downregulation of miR-195 promotes prostate cancer progression by targeting HMGA1.
Zhang X; Tao T; Liu C; Guan H; Huang Y; Xu B; Chen M
Oncol Rep; 2016 Jul; 36(1):376-82. PubMed ID: 27175617
[TBL] [Abstract][Full Text] [Related]
38. Transcriptome Sequencing Reveals PCAT5 as a Novel ERG-Regulated Long Noncoding RNA in Prostate Cancer.
Ylipää A; Kivinummi K; Kohvakka A; Annala M; Latonen L; Scaravilli M; Kartasalo K; Leppänen SP; Karakurt S; Seppälä J; Yli-Harja O; Tammela TL; Zhang W; Visakorpi T; Nykter M
Cancer Res; 2015 Oct; 75(19):4026-31. PubMed ID: 26282172
[TBL] [Abstract][Full Text] [Related]
39. miRNA-30a functions as a tumor suppressor by downregulating cyclin E2 expression in castration-resistant prostate cancer.
Zhang L; Zhang XW; Liu CH; Lu K; Huang YQ; Wang YD; Xing L; Zhang LJ; Liu N; Jiang H; Sun C; Yang Y; Chen SQ; Chen M; Xu B
Mol Med Rep; 2016 Sep; 14(3):2077-84. PubMed ID: 27431942
[TBL] [Abstract][Full Text] [Related]
40. Ultrasound-Induced Microbubble Cavitation Combined with miR-34a-Loaded Nanoparticles for the Treatment of Castration-Resistant Prostate Cancer.
Wang Z; Chen C; Tao Y; Zou P; Gao F; Jia C; Liu L; Li G; Zhang G; Duan Y; Shi Q
J Biomed Nanotechnol; 2021 Jan; 17(1):78-89. PubMed ID: 33653498
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
